Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* LDL-C \> 70 mg/dL and Triglycerides \< 400 mg/dL,~* Treated with a high-intensity statin therapy~Exclusion Criteria:~* BMI \>= 40 kg/m2~* Significant cardiovascular disease~* HbA1c \>= 10%~* Uncontrolled hypertension~* Active muscle disease~* estimated glomerular filtration rate \< 60 mL/min~* Hepatic dysfunction~* History of participation in any clinical trial evaluating obicetrapib~* Anemia~* History of malignancy~* Alcohol abuse~* Treatment with investigational product~* Treatment with PCSK9~* Clinically significant condition~* Known CETP inhibitor allergy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): once-daily placebo tablet and placebo capsule
- monotherapy (Type: EXPERIMENTAL): once-daily obicetrapib 10 mg tablet and placebo capsule
- combination therapy (Type: EXPERIMENTAL): once-daily obicetrapib 10 mg tablet and ezetimibe 10 mg capsule

Based on this trial design, predict the completion outcome and termination type (if applicable).